0
Détail de l'auteur
Auteur M.J. Eisenberg |
Documents disponibles écrits par cet auteur (2)
Ajouter le résultat dans votre panier Affiner la recherche
Feasibility of restricting e-cigarettes to prescription only for smoking cessation / Katya Peri (2024)
Titre : Feasibility of restricting e-cigarettes to prescription only for smoking cessation Type de document : document électronique Auteurs : Katya Peri, Auteur ; M.J. Eisenberg, Auteur Editeur : BioMed Central Année de publication : 2024 Collection : Respiratory Research num. 25 Importance : 4 p. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Canada
[DIVERS] géographie:Océanie:Australie
[DIVERS] personne:par âge:jeune
[TABAC] CANDIDATS:e-cigarette
[TABAC] sevrage tabagique:aide au sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:prescriptionIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : E-cigarette use among youth in Canada has risen to epidemic proportions. E-cigarettes are also moderately useful smoking cessations aids. Restricting e-cigarettes to prescription only smoking cessation aids could help limit youth’s access to them while keeping them available as therapies for patients who smoke conventional cigarettes.
In Canada, drugs or devices must be approved by regulatory bodies such as Health Canada in order to become licensed prescription medications. A similar situation is underway in Australia, where e-cigarettes have been restricted to prescription only. This commentary explores the feasibility of a similar regulation for e-cigarettes in Canada as prescription smoking cessation aids.En ligne : https://doi.org/10.1186/s12931-024-02792-4 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10293 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : The efficacy of smoking cessation therapies in cardiac patients : a meta-analysis of randomized controlled trials Type de document : texte imprimé Auteurs : M.J. Eisenberg, Auteur ; Lisa M. Blum, Auteur ; Kristian B. Filion, Auteur ; Stephane Rinfret, Auteur Editeur : Oakville [Canada] : Canadian Cardiology Publications Inc. Année de publication : 2010 Collection : The Canadian journal of cardiology, ISSN 0828-282X num. 26:2 Importance : p. 73-79 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:thérapie cognitivo-comportementaleIndex. décimale : TA 6.1 Généralités Résumé : Abstract
INTRODUCTION:
Several meta-analyses have examined the efficacy of smoking cessation therapies in the general population. However, little is known about the efficacy of these therapies in cardiac patients. Therefore, a meta-analysis of randomized controlled trials (RCTs) was performed to determine the efficacy of behavioural therapy and pharmacotherapy for smoking cessation in cardiac patients.
METHODS:
The medical literature was systematically reviewed to identify smoking cessation RCTs in cardiac patients. Only RCTs that reported smoking abstinence at six or 12 months were included. Smoking abstinence was examined based on the 'most rigorous criterion', defined as the most conservative outcome reported in any given RCT.
RESULTS:
Eleven behavioural therapy RCTs that enrolled 2105 patients and four pharmacotherapy RCTs that enrolled 1542 patients were identified. RCTs differed in the type of behavioural therapy administered as well as the total length and duration of the intervention. RCTs differed in the type of pharmacotherapy administered (one nicotine patch RCT, one nicotine gum RCT and two bupropion RCTs). Behavioural therapy was associated with a significantly higher proportion of smoking abstinence than usual care (OR 1.97 [95% CI 1.37 to 2.85]). Pharmacotherapies were more efficacious than placebo (pooled OR 1.72 [95% CI 1.15 to 2.57]).
CONCLUSIONS:
Both behavioural therapy and pharmacotherapy are more efficacious than usual care for smoking cessation in cardiac patients. The present meta-analysis highlights the need for head-to-head RCTs to identify which smoking cessation therapy is preferred in cardiac patients as well as RCTs examining the efficacy of combined behavioural and pharmacotherapies.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851386/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8100 Aucun avis, veuillez vous identifier pour ajouter le vôtre !